Drug Profile


Alternative Names: CRx-197; CRx-197 high dose topical cream (0.1% nortriptyline HCl +0.3% loratadine); CRx-197 low dose topical cream (0.1% nortriptyline HCl + 0.1% loratadine); Nortriptyline/loratadine - Zalicus

Latest Information Update: 29 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CombinatoRx
  • Developer Zalicus
  • Class Anti-inflammatories; Antiallergics; Dibenzocycloheptenes; Piperidines; Skin disorder therapies; Tricyclic antidepressants
  • Mechanism of Action Cytokine modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Plaque psoriasis

Most Recent Events

  • 31 Dec 2010 Discontinued - Phase-II for Plaque psoriasis in Germany (Topical)
  • 09 Sep 2010 CombinatoRx is now called Zalicus
  • 14 Jan 2009 CombinatoRx completes a phase II trial for Plaque psoriasis in Germany (NCT00796211)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top